STOK

STOK (Stoke Therapeutics, Inc.) Analyst Note Date: 2026-06-13 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

Current State: Forming Entry Parameters:

• Conservative Entry: Not yet available (requires confirmed breakout above $38.69).
• Aggressive Entry: $35.68 (Pre-breakout / Forming entry).

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Rare & Orphan (Tier Direct, High Confidence). Thesis Context: Stoke Therapeutics is a direct beneficiary of the secular shift toward treating severe, rare genetic disorders where standard of care is limited or non-existent. The company operates in the "Rare & Orphan" sub-sector, which historically commands premium valuations due to high unmet medical need and potential for orphan drug designations. Conviction Weighting: The setup is reinforced by the company's specific focus on Dravet syndrome and Autosomal Dominant Optic Atrophy (ADOA). While the "Biotech & GLP-1" label in the membership list is a broad categorization, the direct exposure to "Rare & Orphan" via the TANGO platform provides a concentrated secular tailwind. The company is not merely a generic biotech; it is a specialized platform play targeting specific, high-value orphan indications.

3. Business Overview

Company Role: Stoke Therapeutics is a late-stage clinical biopharmaceutical company developing innovative antisense oligonucleotide (ASO) therapies. Business Model: The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. The business model relies on advancing these candidates through clinical trials to secure regulatory approval (NDA) and commercialize the drugs, potentially through direct sales or licensing partnerships. Key Evidence (as of 2026-06-13):

• Pipeline Status: The company's lead candidate, zorevunersen (STK-001), is in late-stage clinical testing for Dravet syndrome. The global Phase 3 EMPEROR study was initiated in May 2025, with the first patient dosed in August 2025.
• Secondary Pipeline: STK-002 is being evaluated for ADOA. The first patient in the OSPREY Phase 1 study was dosed in February 2026.
• Commercial Partnerships: As of the latest filings, Stoke is collaborating with Biogen on the development and commercialization of zorevunersen outside the U.S., Canada, and Mexico.
• Financial Position: As of March 31, 2026, the company reported $411.0 million in cash, cash equivalents, and marketable securities. This follows a capital raise in early 2026, where approximately 3.2 million shares were issued for net proceeds of $87.8 million.
• Management Expectations: Management expects to complete enrollment of approximately 150 patients in the EMPEROR study in the second quarter of 2026. They anticipate pivotal Phase 3 data in mid-2027 to support an NDA submission, with a plan to initiate a rolling NDA submission in the first half of 2027.

4. Archetype and Conviction

Archetype: Growth Leader Rationale: The company fits the "Growth Leader" archetype due to its progression into late-stage clinical trials (Phase 3) for a high-value orphan indication, supported by a robust cash runway and strategic partnerships. The business is transitioning from pure R&D to a de-risked commercialization phase. Valuation & Financials: The financial spine indicates a forward consensus EPS of -3.22 for FY1 and -3.12 for FY2, reflecting the pre-revenue nature of the company. However, the strong balance sheet ($411M cash) mitigates immediate dilution risk. Conviction Stack:

• Thesis Strength: High. The "Rare & Orphan" theme is robust, and the specific disease targets (Dravet, ADOA) have clear unmet needs.
• Evidence Quality: Strong. Multiple primary SEC filings (May 2026, March 2026) confirm trial initiation, dosing, and financial health.
• Setup Readiness: Partial. The "Forming" state requires a breakout above $38.69 to confirm the next leg up. The 69% historical breakout rate for this setup type provides a statistical edge, but it is not a guarantee.
• Rerating Potential: Significant. Successful Phase 3 data in mid-2027 could trigger a major re-rating from a clinical-stage valuation to a commercial-stage valuation.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• Fundamental: Any adverse data readout from the EMPEROR study (e.g., failure to meet primary endpoints) or a significant delay in the OSPREY study would fundamentally break the growth thesis.
• Capital: A sudden, unexpected need for capital raising that dilutes existing shareholders significantly, given the current $411M cash position.

What Would Strengthen:

• Technical: A confirmed daily close above $38.69 (Breakout Level) would convert the setup to "Confirmed-Active," validating the bullish structure.
• Fundamental: Positive interim data from the OSPREY study or an update on the Biogen partnership terms.
• Regulatory: FDA designation (e.g., Orphan Drug, Fast Track) for STK-001 or STK-002.

Gaps in Evidence:

• Specific Trial Metrics: While the initiation and dosing dates are known, specific efficacy data points (e.g., seizure frequency reduction percentages) from the EMPEROR study are not yet available in the provided evidence as of June 2026, as enrollment is expected to complete in Q2 2026.
• Commercialization Timeline: While management expects an NDA in mid-2027, the exact timeline for FDA review and potential approval remains a structural implication rather than a confirmed date.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: 1) Technical invalidation if price closes below $30.50; 2) Clinical trial failure or delay in EMPEROR study results; 3) Dilution risk if cash runway is insufficient for full commercialization. Sizing hint: Position size should reflect the "Forming" state; smaller than a confirmed breakout, larger than a pure speculative gamble. Expected path: Management expects to complete enrollment in Q2 2026, followed by pivotal data in mid-2027, potentially leading to a rolling NDA submission in H1 2027. Expected horizon: 12 to 18 months for the thesis to play out (data readout to NDA filing). Failure mode to watch: A daily close below $30.50, which would signal a breakdown of the support structure and invalidate the setup.